Financial Daily from THE HINDU group of publications
Wednesday, Jun 22, 2005
News
Features
Stocks
Port Info
Archives
Google

Group Sites

 Corporate - People


Dr Rader joins Dr Reddy's board

Our Bureau

HYDERABAD: Dr Reddy's Laboratories Ltd has announced that Dr Daniel Rader from the University of Pennsylvania in Philadelphia has joined the company's Scientific and Clinical Advisory Board.

In a press release here on Tuesday, the company said Dr Rader is a faculty in the Department of Medicine and the Director of Cardiovascular Metabolism unit at the Institute for Diabetes, Obesity and Metabolism. He is a global thought leader in the areas of dyslipidemia and cardiovascular disease.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Kinetic unveils Italijet

Aurobindo Pharma gets USFDA nod for another ARV
Balrampur Chini exits branded sugar biz
SPIL taps salt farmers of Gujarat for SS pumps
German DFI to pick up 15% stake in Aarvee Denim
Pitti to issue pref shares
Wal-Mart award for Ranbaxy arm
Govt may raise ICAI council strength to 35 members
India Inc eyes high earnings from carbon trading
Viceroy may hive off US arm
Forbes Gokak to merge FAL with itself
BMW may set up shop in Mahindra Industrial Park
Uttam Steel plans to double capacity
Sigma Hospitals to expand
Hilton pact with Embassy Group for managing apartment block
Arch Pharma, Spanish co tie up
Suryalakshmi Cotton to issue 1:1 bonus shares
Dutch certification for NMDC
Crompton Greaves open to buys in industrial systems
LG Electronics eyes 25 pc growth in CTV sales
Parryware eyes 40 per cent rise in sales in Kerala
Gujarat Gas may not take stake in Adani group arm
Serious frauds office allowed to file complaints under IPC
Sanjeev Sethi joins Matrix Labs
Dr Rader joins Dr Reddy's board

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line